TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis

Fengqin Dong1, Qi Ling2, Dan Ye1, Zhe Zhang1, Jing Shu3, Guoping Chen1, Yang Fei4 & Chengjiang Li1

To evaluate the role of TCF7L2, a key regulator of glucose homeostasis, in estradiol (E2) and progesterone (P4)-modulated glucose metabolism, mouse insulinoma cells (MIN6) and human liver cancer cells (hepG2 and HUH7) were treated with physiological concentrations of E2 or P4 in the up- and down-regulation of TCF7L2. Insulin/proinsulin secretion was measured in MIN6 cells, while glucose uptake and production were evaluated in liver cancer cells. E2 increased insulin/proinsulin secretion under both basal and stimulated conditions, whereas P4 increased insulin/proinsulin secretion only under glucose-stimulated conditions. An antagonistic effect, possibly concentration-dependent, of E2 and P4 on the regulation of islet glucose metabolism was observed. After E2 or P4 treatment, secretion of insulin/proinsulin was positively correlated with TCF7L2 protein expression. When TCF7L2 was silenced, E2- or P4-promoted insulin/proinsulin secretion was significantly weakened. Under glucotoxicity conditions, overexpression of TCF7L2 increased insulin secretion and processing. In liver cancer cells, E2 or P4 exposure elevated TCF7L2 expression, enhanced the activity of insulin signaling (pAKT/pGSK), reduced PEPCK expression, subsequently increased insulin-stimulated glucose uptake, and decreased glucose production. Silencing TCF7L2 eliminated effects of E2 or P4. In conclusion, TCF7L2 regulates E2- or P4-modulated islet and hepatic glucose metabolism. The results have implications for glucose homeostasis in pregnancy.

Gestational diabetes mellitus (GDM) is seen commonly during pregnancy in predisposed individuals. It is characterized by a combination of reduced maternal insulin secretion and impaired insulin sensitivity. GDM can cause severe maternal and neonatal adverse effects. In the past several decades, the prevalence of GDM has markedly increased worldwide, which is likely due, at least in part, to increased maternal weight1–3.

GDM usually develops during the second trimester when estradiol (E2) and progesterone (P4) levels sharply increase4. In predisposed individuals, the production of placental hormones can lead to maternal insulin resistance, which in turn can contribute to the development of GDM. Adapting to insulin resistance, sex hormones can modulate pancreatic islets to adapt to insulin resistance. For instance, E2 acts directly on β cells to increase insulin biosynthesis and enhance glucose-stimulated insulin secretion4, and also reduces hepatic and muscle insulin resistance5. Physiologically elevated P4 levels stimulates islet cell proliferation6. However, if β-cell functions do not adapt to increased insulin demand, GDM may develop. Other identified risk factors for GDM include advanced maternal age, obesity, ethnicity or race (e.g., Asians), previous history of GDM, and family history of diabetes mellitus1.

Genetic background also contributes to development of GDM7. Recent systematic reviews reported a significant association between GDM risk and genetic polymorphisms8,9. Genetic variants of transcription factor 7-like 2 (TCF7L2) demonstrated the strongest association with GDM risk in women of different races and ethnicities8. The risk T allele of rs7903146 was associated with increased TCF7L2 protein expression, as well as decreased insulin content and secretion10,11. TCF7L2, also known as TCF4, is the effector of the Wnt signaling pathway and considered to serve as an important regulator of glucose homeostasis by regulating proinsulin production and
processing. Additionally, TCF7L2 may affect hepatic glucose metabolism by suppressing gluconeogenesis. However, the underlying regulatory properties of TCF7L2 in the development of GDM have not previously been described. In this study, we evaluated E2- and P4-modulated glucose homeostasis in islets and liver to further assess the physiological relationship between these hormones and TCF7L2.

Research Design and Methods

Cell culture and transfection. Human hepatocarcinoma cells (HepG2 and HUH7), mouse insulinoma (MIN6) cells, and 293T cells, obtained from the Chinese Academy of Science, were cultured in DMEM containing fetal calf serum (10%; Hyclone), penicillin (100 U/ml), streptomycin (100 μg/ml), and 1% Glutamax in 5% CO2. E2 and P4 were obtained from Sigma-Aldrich.

HepG2 and MIN6 cells were seeded in a six-well culture plate at a density of 5 × 104 cells/well. After 24 h, 400 μl of DMEM (serum-free and antibiotic-free) was added with 4 μg of DNA from pcDNA6.2-GFP-TCF7L2 (full-length TCF7L2, Invitrogen) and pcDNA6.2-EGFP-empty control plasmid or 4 μg of DNA from pcDNA6.2-GW/EGFP-miR-TCF7L2 (NCBI: NM_001146284.1; Supplemental Table 1) and pcDNA6.2-GW/EGFP-miR-NC plasmid, respectively, then mixed thoroughly. Cell suspensions were thoroughly mixed with 9 μl of Lipofectamine™ 2000 transfection reagent and allowed to stand at room temperature for 10 min to form transfection complexes. The complexes were added to the cells and cocultured at 37°C in a 5% CO2 incubator. The cells were collected at 24–72 h after transfection. The pcDNA6.2-GW/EGFP-miR-TCF7L2 plasmid producing the highest knockdown of TCF7L2 mRNA and protein expression was used for subsequent experiments.

Cell viability assay. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously reported. Briefly, cells (1 × 104 cells/well) were seeded in 96-well plates and incubated overnight. The original medium was replaced with fresh medium containing vehicle control or sex hormones for another 24 h. The MTT solution (2 mg/ml) was added to each well and incubated for 4 h. After centrifugation at 1000 rpm for 10 min, the medium was removed, and the MTT formazan precipitate was dissolved in 100 μl of DMSO. Absorbance was measured at 570 nm with a plate reader (Opsys MR, Denex Technology, USA).

Proinsulin and insulin release tests. MIN6 cells (5 × 104 cells/well) were seeded in six-well plates and incubated overnight. Cells were treated with the vehicle control or sex hormones for 24 h. Proinsulin or insulin was released into the medium and measured using the proinsulin or insulin ELISA kit. The proinsulin or insulin secretion was normalized to viable cell numbers.

Glucose uptake and production assays. Cells (2.5 × 104 cells/well) seeded in six-well plates were treated with sex hormones for 24 h. The medium was replaced with serum- and glucose-free DMEM for another 4 h. The cells were then washed with PBS and incubated in serum- and glucose-free DMEM containing the fluorescent glucose analog 2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose (2-NBDG, 40 μM) and insulin (100 nM) for 30 min. After incubation, cells were washed with PBS, and fluorescence retained by the cells was measured by flow cytometry (BD Bioscience, San Jose, California, USA). Data from 10,000 cells were collected and analyzed.

Cells (5 × 104 cells/well) seeded in 24-well plates were treated with sex hormones for 24 h. The medium was then replaced with serum- and glucose-free DMEM containing 20 mmol/l D-lactate and 2 mmol/l sodium pyruvate for 20 h. The medium was subsequently assayed for glucose with a commercial kit (Invitrogen). The glucose production was normalized to viable cell numbers.

Qualitative RT-PCR. Total RNA was extracted using a commercial kit, and real-time PCR was performed with the 9700 Real-time PCR System (Applied Biosystems, Carlsbad, California, USA) and the SDS 2.1 software (Applied Biosystems). The PCR primers are shown in Supplemental Table 2. Each PCR run started with the incubation of samples at 50°C for 2 min, followed by incubation at 95°C for 10 min, and 40 cycles of incubation at 95°C for 15 s and at 59°C for 30 s. Data were normalized by quantifying the amount of amplified cDNA products by calculating the ratio of the amount of cDNA relative to the amount of GAPDH cDNA.

Western blot analysis. Western blot analysis was performed as previously reported. The antibodies previously used for Western blots were the anti-human TCF7L2 antibody (1:800; 13838-1-AP, Proteintech, USA), anti-human PEPCK antibody (1:1000; 14892-1-AP, Proteintech, USA), anti-human GLUT2 antibody (1:800; 20436-1-AP, Proteintech, USA), anti-human IRS2 antibody (1:1000; 20702-1-AP, Proteintech, USA), anti-human pAKT antibody (1:1000; 60072-1-Ig; Proteintech, USA), anti-human AKT antibody (1:1000; 10176-2-AP; Proteintech, USA), anti-human IRS2 antibody (1:1000; 20702-1-AP; Proteintech, USA), anti-human PEPCK antibody (1:1000; 14892-1-AP; Proteintech, USA), anti-human GLUT2 antibody (1:800; 20436-1-AP; Proteintech, USA), anti-human pAKT antibody (1:1000; 60072-1-Ig; Proteintech, USA), anti-human AKT antibody (1:1000; 10176-2-AP; Proteintech, USA), anti-human pGSK antibody (1:1000; 14850-1-AP; Proteintech, USA), anti-human GSK antibody (1:1000; 22104-1-AP; Proteintech, USA), anti-human ERK1/2 antibody (1:1000; 16443-1-AP; Proteintech, USA), anti-human pERK1/2 antibody (1:1000; 3441-1-AP; BioVision, USA), anti-human PEPCK antibody (1:1000; 14892-1-AP; Proteintech, USA), anti-human GLUT2 antibody (1:800; 20436-1-AP; Proteintech, USA), anti-human pAKT antibody (1:1000; 60072-1-Ig; Proteintech, USA), anti-human AKT antibody (1:1000; 10176-2-AP; Proteintech, USA), anti-human pGSK antibody (1:1000; 14850-1-AP; Proteintech, USA), anti-human GSK antibody (1:1000; 22104-1-AP; Proteintech, USA), anti-human ERK1/2 antibody (1:1000; 16443-1-AP; Proteintech, USA), and anti-human GAPDH antibody (1:1000; 10494-1-AP; Proteintech, USA). GAPDH was used as control. The results were quantified by the ImagePro Plus 5.1 software (Media Cybernetics, Inc., USA).

Statistical analysis. Statistical analyses were performed with SPSS for Windows version 13.0 (SPSS, Inc., Chicago, USA). Values with P < 0.05 were considered statistically significant. The Kolmogorov–Smirnov test was used to check the normality. Quantitative variables were expressed as mean ± SD or median. Categorical variables were presented as values and percentages. One-way ANOVA with Dunnett's t-test, Student's t-test, Wilcoxon–Man–Whitney test, and chi-square test were used to compare the variables. Pearson correlation test was used for correlation analysis.
Results

Effects of estradiol and progesterone on β-cell survival and function. To evaluate the effects of E₂ and P₄ on β-cell proliferation, we treated MIN6 cells with 100 nM E₂, 1 μM P₄, or 100 nM E₂ plus 1 μM P₄. We found that the sole use of E₂ or P₄ increased the number of viable cells (Fig. 1A), but E₂ and P₄ together significantly decreased the number of viable cells at 24, 48, and 72 h (Fig. 1A, P < 0.05).

E₂ can stimulate progesterone receptor (PR) activity15. Overactivation of PR/PR signaling exerted an unfavorable effect on β-cell survival and function16–21. Thus, we further exposed the cells to a low concentration of E₂ (10 nM) plus P₄ and found a significant increase in the number of viable cells compared with those treated with high concentration of E₂ (100 nM) plus P₄ (Fig. 1A, P < 0.05). A similar result was observed after PR was blocked with antagonist RU486 (40 μM) but not after ER was blocked with ICI182780 (10 μM) (Fig. 1A).

Insulin and proinsulin secretion were evaluated after sex hormone treatment in MIN6 cells. When the cells were cultured in E₂ alone for 24 h, they exhibited significantly increased insulin/proinsulin secretion under basal and glucose-stimulated conditions (Fig. 1B, C, P < 0.05) compared with the control cells. Cells treated with P₄ alone showed significantly increased insulin/proinsulin secretion only under glucose-stimulated conditions (Fig. 1B, C, P < 0.05). However, co-treatment of E₂ and P₄ demonstrated a much weaker effect on insulin/proinsulin secretion than the effect caused by E₂ or P₄ treatment alone. After reducing the concentration of E₂ or blocking PR, cells treated with E₂ plus P₄ showed significantly increased insulin/proinsulin secretion (Fig. 1B, C, P < 0.05). The insulin/proinsulin stimulatory index and insulin processing capability (reflected by the proinsulin-to-insulin ratio) followed the same tendency as the insulin/proinsulin secretory dynamic (Fig. 1D–F).

Silencing of TCF7L2 weakens estradiol- and progesterone-promoted β-cell insulin secretion. To assess the role of TCF7L2 in E₂- or P₄-modulated β-cell function, we analyzed the TCF7L2 protein content after sex hormone exposure. E₂ markedly increased TCF7L2 protein content under both basal and stimulated conditions, whereas P₄ sharply increased TCF7L2 protein content under stimulated conditions (Fig. 2A). Similar effect was found in TCF7L2 mRNA levels after sex hormone exposure (Supplemental Fig. 1). The TCF7L2 protein content showed a significantly positive correlation with the insulin/proinsulin secretion after E₂ or P₄ treatment (Supplemental Table 3; Figs 1 and 2).

We knocked down TCF7L2 in MIN6 cells and found that the number of viable cells significantly decreased at 24, 48, and 72 h (Fig. 2B, P < 0.05). Decreased TCF7L2 expression led to significantly lower insulin/proinsulin secretion (Fig. 2C, D, P < 0.05). More importantly, the downregulation of TCF7L2 markedly weakened the E₂- or P₄-promoted insulin/proinsulin secretion (Fig. 2C, D, P < 0.05). E₂ did not significantly change the insulin stimulatory index, whereas P₄ remarkably increased insulin and proinsulin stimulatory indexes (Fig. 2E, F). The downregulation of TCF7L2 weaken the P₄-elevated insulin/proinsulin stimulatory index (Fig. 2E, F). Furthermore, P₄-promoted insulin processing persisted after the downregulation of TCF7L2, as reflected by the significantly decreased proinsulin-to-insulin ratio compared with that of the control (Fig. 2G, P < 0.05).

Overexpression of TCF7L2 increases insulin secretion and processing under glucotoxicity status. To mimic diabetic glucotoxicity, we exposed MIN6 cells to a high glucose concentration (33.3 mM) for 72 h. Although an increase in basal secretion of insulin was observed, we found significantly reduced insulin secretion and increased proinsulin-to-insulin ratio at stimulated conditions in high glucose-exposed MIN6 cells compared with 5.5 mM glucose-cultured cells (P < 0.05), thereby indicating impaired glucose-stimulated insulin secretion and processing capability in the setting of glucotoxicity.

Under glucotoxicity conditions, we found that P₄ cannot stimulate TCF7L2 protein content (Fig. 3A) and cannot reduce the proinsulin-to-insulin ratio under stimulated condition (Fig. 3G). By contrast, E₂ treatment was associated with similar effects on insulin and proinsulin secretion as under normal conditions (Figs 2 and 3).

Overexpression of TCF7L2, led to increased number of viable cells (Fig. 3B), significantly increased basal and stimulated insulin secretions (Fig. 3C, P < 0.05) and enhanced insulin processing capability, as reflected by a significantly decreased proinsulin-to-insulin ratio under glucotoxicity conditions (Fig. 3G, P < 0.05). However, the stimulatory indexes remained unchanged (Fig. 3F, P > 0.05).

TCF7L2 participates in estradiol- and progesterone-regulated hepatic glucose metabolism. Since the liver plays a central role in controlling glucose uptake and production, we assessed the effect of sex hormones on hepatic glucose metabolism. We treated HepG2 and HUH7 cells with 100 nM E₂, 1 μM P₄, or 100 nM E₂ plus 1 μM P₄. The numbers of viable cells were similar in each sex hormone-treated group compared with the controls at 24, 48, and 72 h (P > 0.05). We also found a significantly increased insulin-stimulated glucose uptake and decreased glucose production after E₂, P₄, or combined treatment (Fig. 4A, B). Moreover, TCF7L2 protein content markedly increased after E₂, P₄, or combined treatment (Fig. 4C).

After TCF7L2 downregulation in HepG2 cells, the effect caused by E₂ or P₄ disappeared (Fig. 5A, C). Overexpression of TCF7L2 increased insulin-stimulated glucose uptake and decreased glucose production in cells with or without sex hormone treatment (Fig. 5B, D).

To further investigate the mechanism of sex hormone-modulated hepatic glucose metabolism, we examined the expression of several key molecules after E₂ or P₄ treatment. We found that both E₂ and P₄ reduced the expression of PEPCK but increased the expression of pAKT, pGSK, and pERK1/2 proteins (Fig. 5E). By silencing TCF7L2, the effect of E₂- and P₄-stimulated phosphorylation of AKT, GSK, and ERK1/2 was significantly weakened. However, P₄ induced the elevated IRS2 expression in the presence and absence of TCF7L2. Additionally, silencing of TCF7L2 increased the PEPCK expression but decreased the expression of GLUT2 and IRS2 in each group (Fig. 5E), whereas overexpression of TCF7L2 produced the opposite effect (Fig. 5F). The quantification of western blots is presented in Supplemental Fig. 2. We also found the same effects of E₂ and P₄ in mRNA levels of PEPCK, GLUT2, and IRS2 (Supplemental Fig. 3).
Figure 1. Effects of estradiol (E2) and progesterone (P4) on β-cell survival and function. MIN6 cells were plated at 5 × 10^5 cells per well in 6-well plates and treated with different combination of E2 (10 or 100 nM), P4 (1 μM), progesterone receptor antagonist (RU486 40 μM) and estradiol receptor antagonist (ICI182780 10 μM) for 24 h. The concentrations of hormones are in the physiological ranges. (A) Viable cells. (B,C) Basal and stimulated insulin/proinsulin secretions (normalized to viable cell numbers). (D,E) Stimulatory indexes. (F) Proinsulin-to-insulin ratio. *P < 0.05 vs. blank control; #P < 0.05 vs. E2 (100 nM) plus P4 (1 μM).
Figure 2. Silencing of TCF7L2 reduces estradiol (E2)- and progesterone (P4)-promoted β-cell insulin/proinsulin secretion. MIN6 cells were plated at 5 × 10⁵ cells per well in 6-well plates and exposed to a TCF7L2-specific short hairpin RNA (shTCF7L2) or a scrambled shRNA (shScr) for 72 h, then cultured for 24 h in the presence of 100 nM E2 or 1 μM P4. (A) Western blots showing the TCF7L2 protein content after E2 or P4 treatment. (B) Viable cells. (C,D) Basal and stimulated insulin/proinsulin secretions (normalized to viable cell numbers). (E,F) Stimulatory indexes. (G) Proinsulin-to-insulin ratio. *P < 0.05 vs. sex hormone treatment control; #P < 0.05 shTCF7L2 vs. shScr.
Figure 3. Overexpression of TCF7L2 increases insulin processing under glucotoxicity status. MIN6 cells were plated at $5 \times 10^5$ cells per well in 6-well plates and exposed to high glucose concentration (33.3 mM) and transfected with TCF7L2-IRE2-EGFP (OE-TCF7L2) or a control vector (CV) for 72 h, then cultured for 24 h in the presence of 100 nM E$_2$ or 1 μM P$_4$. (A) Western blots showing the TCF7L2 protein content after E$_2$ or P$_4$ treatment. (B) Viable cells. (C,D) Basal and stimulated insulin/proinsulin secretions (normalized to viable cell numbers). (E,F) Stimulatory indexes. (G) Proinsulin-to-insulin ratio. *$P < 0.05$ vs. sex hormone treatment control; #$P < 0.05$ OE-TCF7L2 vs. CV.
Discussion

The increased levels of estrogenic and progestational hormones can generally lead to insulin resistance and elevated glucose levels. However, pregnant women were found to exhibit lower blood glucose levels than those of non-pregnant ones. Updated guidelines recommend lower blood glucose values to diagnose GDM.

E2 and P4 induce opposing physiological effects on the female reproductive system and other organ systems, such as the cardiovascular system. The present study demonstrates that the two sex hormones may exert an antagonistic effect on regulating islet glucose homeostasis. Our results reveal that acute treatment of E2 or P4 leads to elevated β-cell proliferation, increased insulin/proinsulin production. This response seems to be an adaptation of islets to maintain maternal glucose homeostasis, even under conditions of gluotoxicity. However, combined E2 and P4 exposure resulted in an opposite effect, namely decreased cell proliferation and reduced glucose-stimulated responsivity and insulin processing. A previous report implied that the antagonistic effect permitted P4 to stimulate islet cell proliferation, but the effect was suppressed by E2 supplementation. However, the sole use of E2 did not affect β-cell proliferation but prevented apoptosis under oxidative stress injury.

To explain this series of events, it is necessary to focus first on the paradoxical effect of P4 on β-cells. Previous studies have shown that the physiological concentration of P4 stimulates β-cell proliferation and increases insulin secretion under conditions of oxidative stress. By contrast, pharmacological or supra-physiological concentrations of P4 will exert an unfavorable effect on β-cell survival and function. Overstimulation of P4/PR signaling will lead to reduced β-cell viability. E2 can markedly stimulate PR activity in β cells; thus, we assumed that E2 may reinforce P4/PR signaling and cause an amplification effect. As expected, we found that the antagonistic effect can be significantly attenuated by reducing the concentration of E2 during cotreatment or by inhibiting the PR. By contrast, the ER antagonist cannot achieve such an effect because it inhibits the E2 signal but, moreover, cannot influence overstimulated P4/PR signaling. Overall, our results suggest a role for the interplay between sex hormones and the development of GDM. However, further studies are with regard to this observation.

TCF7L2 is the most powerful, recognized susceptibility gene for diabetes. The association of TCF7L2 gene polymorphisms with almost all subtypes of diabetes (e.g., type 1 and 2 diabetes, latent autoimmune diabetes in adults, hepatogenous diabetes, and post-transplant diabetes) has been demonstrated. Zhou et al. proposed a master role for TCF7L2 in regulating insulin biosynthesis, secretion, and processing. However, evidence from Boj et al. was less convincing. Our results revealed that TCF7L2 was essential for glucose-stimulated insulin/proinsulin secretion and processing, as well as β-cell proliferation. Furthermore, under conditions of gluotoxicity, the overexpression of TCF7L2 will markedly increase insulin processing and secretion. These findings attest to the significant role of TCF7L2 in islet function and indicate a potential clinical role of TCF7L2 in treating diabetes.

We further found a positive correlation between P4- or P4-promoted insulin/proinsulin secretion. Downregulation of TCF7L2 remarkably weakened the effect induced by E2 or P4, thereby indicating that E2- or P4-promoted insulin/proinsulin secretion can, at least in part, be TCF7L2 dependent. Moreover, the E2-promoted stimulated insulin processing is TCF7L2 required; whereas the P4-promoted stimulated insulin processing may be independent of TCF7L2 because the effect persisted in the absence of TCF7L2 expression. In addition, TCF7L2 may not be essential for the E2- or P4-increased stimulatory index since downregulation of TCF7L2 did not alter the effects in stimulatory index. Under conditions of gluotoxicity, E2 increased TCF7L2 protein content under basal and stimulated conditions as it did under the normal, non-gluotoxic conditions to achieve similar effects on β-cell secretion. In contrast, P4 did not further increase TCF7L2 protein content under stimulated conditions. Thus, insulin processing was unaffected. P4 still induced enhanced insulin/proinsulin secretion under stimulated conditions. The results suggest that TCF7L2 is essential for insulin processing. However, TCF7L2 was not required for P4-promoted stimulated insulin/proinsulin secretion in β cells that were gluotoxic.

Given the central role of the liver in the regulation of glucose homeostasis, we also assessed the effects of E2 and P4 on hepatic glucose metabolism. Although the opposing effects of E2 and P4 on oxidative stress processes have been reported in vitro, a recent in vivo study using microarray analysis showed that E2, P4, and their co-treatment actually displayed similar patterns and networks of hepatic gene expression. Consistent with the previous study, we found that E2 and P4 presented similar phenotypes and protein content profiles in regulating
hepatic glucose metabolism. Both E2 and P4 can improve insulin-stimulated glucose uptake, possibly through the enhanced activation of hepatic insulin signaling (pAKT/pGSK). E2 and P4 can also reduce gluconeogenesis by repressing PEPCK expression. Both E2 and P4 significantly increased hepatic ERK activation, which can increase glycogen synthesis and attenuate glucose output. In addition, the opposing effects of P4 and E2 were detected in the expression of IRS2 and GLUT2, which may further explain the stronger effect of P4 than E2 in regulating hepatic glucose uptake.

Combined with previous studies, our study has demonstrated that TCF7L2 represses hepatic glucose production by regulating gluconeogenic genes. In addition, we revealed that TCF7L2 mediated hepatic insulin

Figure 5. TCF7L2 involves in estradiol (E2)- and progesterone (P4)-regulated hepatic glucose metabolism. HepG2 cells (2.5 × 10^5 cells per well) were seeded in 6-well plates and exposed to a TCF7L2-specific short hairpin RNA (shTCF7L2) or a scrambled shRNA (shScr) for 72 h, or transfected with TCF7L2-IRES2-EGFP (OE-TCF7L2) or a control vector (CV) for 72 h, then cultured for 24 h in the presence of 100 nM E2 or 1 μM P4. (A,B) 2-NBDG uptake. (C,D) Glucose production. (E,F) Western blot. *P < 0.05 vs. sex hormone treatment control; #P < 0.05 shTCF7L2 vs. shScr or OE-TCF7L2 vs. CV.
signaling (IRS2-AKT-GSK), glucose sensing (GLUT2), and energy metabolism (ERK). Norton et al. have revealed that TCF7L2 binds directly to multiple genes that are important in hepatic glucose metabolism (e.g., PCK1, IRS2, AKT2 and PDK4) using CHIP-Seq in vitro38. Therefore, TCF7L2 may modulate hepatic glucose homeostasis in various ways far more than gluconeogenesis38. Moreover, this study demonstrates that TCF7L2 is involved in E2- or P4-modulated liver glucose metabolism. E2, or P4-stimulated activation of AKT/GSK and ERK1/2 signaling seems to be TCF7L2-dependent because silencing of TCF7L2 clearly reverses sex hormone-induced phosphorylation of AKT/GSK and ERK1/2 proteins. In contrast, the P4-induced overexpression of IRS2 may be TCF7L2-independent because the effect did not diminish after the silencing of TCF7L2.

This study has several limitations. First, the interplay between different concentrations of E2 and P4 is complex. We did not assess the correlation between TCF7L2 and E2 plus P4. The genomic and non-genomic mechanisms of the antagonistic effect need further research in future well-designed studies. Second, this work is an in vitro study with short-term sex hormone treatment. Thus, in vivo studies are needed to further document our findings.

In conclusion, both E2 and P4 at physiological concentrations modulate glucose homeostasis to meet pregnancy demands, including increased insulin secretion and processing, enhanced hepatic insulin signaling, and reduced gluconeogenesis. The reported insulin resistance caused by E2 or P4 may be attributable to other mechanisms, such as peripheral insulin resistance and insulin binding38,39. The antagonistic effect of E2 and P4 on the regulation of islet glucose metabolism, possibly concentration-dependent, was also observed. Therefore, pregnant women with different combinatorial amounts of sex hormones may be at differential risk for developing GDM. Finally, TCF7L2 is an important regulator of both islet and hepatic glucose metabolism. TCF7L2 participates in E2- or P4-modulated glucose homeostasis, particularly in hepatic glucose production. Compared with P4, E2 seems to be more dependent upon expression of TCF7L2 to regulate glucose metabolism.

References

1. Tutino, G. E. et al. Diabetes and pregnancy: perspectives from Asia. Diabet Med 31, 302–318 (2014).
2. Ferrara, A. Increasing prevalence of gestational diabetes mellitus: a public health perspective. Diabetes Care 30 Suppl 2, S141–146 (2007).
3. Liu, L., Hong, Z. & Zhang, L. Associations of preconception body mass index and gestational weight gain with pregnancy outcomes in nulliparous women delivering single live babies. Sci Rep 5, 12663 (2015).
4. Nadal, A., Alonso-Magdalena, P., Soriano, S., Ropero, A. B. & Quesada, I. The role of oestrogens in the adaptation of islets to insulin resistance. J Physiol 587, 5031–5037 (2009).
5. Camporez, J. P. et al. Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance. Endocrinology 154 (2013).
6. Nieuwenhuizen, A. G. et al. Progesterone stimulates pancreatic cell proliferation in vivo. Eur J Endocrinol 140, 256–263 (1999).
7. Anguera, A. R. et al. New insights into gestational glucose metabolism: lessons learned from 21st century approaches. Diabetes 64, 327–334 (2015).
8. Zhang, C. et al. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. Hum Reprod Update 19, 376–390 (2013).
9. Zhang, Y., Sun, C. M., Hu, X. Q. & Zhao, Y. Relationship between melatonin receptor 1B and insulin receptor substrate 1 polymorphisms with gestational diabetes mellitus: a systematic review and meta-analysis. Sci Rep 4, 6113 (2014).
10. Zhou, Y. et al. TCF7L2 is a master regulator of insulin production and processing. Hum Mol Genet 23, 6419–6431 (2014).
11. Wagner, R. et al. Clinical and non-targeted metabolic profiling of homoygous carriers of Transcription Factor 7-like 2 variant rs7903146. Sci Rep 4, 5296 (2014).
12. Takamoto, I. et al. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia 57, 542–553 (2014).
13. Neve, B. et al. Alternative human liver transcripts of TCF7L2 bind to the gluconeogenesis regulator HNF4alpha at the protein level. Diabetologia 57, 785–796 (2014).
14. Boj, S. F. et al. Diabetes risk gene and Wnt effector Tcf7l2/Tcf4 controls hepatic response to perinatal and adult metabolic demand. Cell 151, 1595–1607 (2012).
15. Oh, K. J. et al. TCF7L2 modulates glucose homeostasis by regulating CREB- and FoxO1-dependent transcriptional pathway in the liver. Plos Genet 8, e1002896 (2012).
16. Ip, W. et al. Liver-specific Expression of Dominant Negative Transcription Factor 7-like 2 Causes Progressive Impairment in Glucose Homeostasis. Diabetes, 64, 1923–1932 (2015).
17. Ling, Q. et al. Oximatrexate induces human pancreatic cancer Panc-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res 30, 66 (2011).
18. Sutter-Dah, M. T. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids 67, 77–93 (2002).
19. Picard, F. et al. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc Natl Acad Sci USA 99, 15644–15648 (2002).
20. Zhou, R. et al. Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability. Steroids 78, 987–995 (2013).
21. Nunes, V. A. et al. Progesterone induces apoptosis of insulin-secreting cells: insights into the molecular mechanism. J Endocrinol 221, 273–284 (2014).
22. Pedersen, S. H., Nielsen, L. B., Mortensen, A., Nilas, L. & Ottesen, B. Progestins oppose the effects of estradiol on the endothelin-1 receptor type B in coronary arteries from ovariectomized hyperlipidemic rabbits. Menopause 15, 503–510 (2008).
23. Alonso-Magdalena, P. et al. Pancreatic insulin content regulation by the estrogen receptor ER alpha. Plos One 3, e2069 (2008).
24. Le May, C. et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103, 9232–9237 (2006).
25. Ahangarpour, A., Heidari, H., Mard, S. A., Hashemitabar, M. & Khodadadi, A. Progesterone and cilostazol protect mice pancreatic islets from oxidative stress induced by hydrogen peroxide. Iran J Pharm Res 13, 937–944 (2014).
26. Straub, S. G., Sharp, G. W., Meglissant, M. D. & De Souza, C. J. Progesterone inhibits insulin secretion by a membrane delimited, non-genomic action. Biocybern Biomed Eng 21, 653–666 (2001).
27. Basile, K. J., Guy, V. C., Schwartz, S. & Grant, S. F. Overlap of genetic susceptibility to type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults. Curr Diab Rep 14, 550 (2014).
28. Ling, Q. et al. Impacts of TCF7L2 gene polymorphisms on the susceptibility of hepatogenous diabetes and hepatocellular carcinoma in cirrhotic patients. Gene 522, 214–218 (2013).
29. Ling, Q. et al. Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol 58, 271–277 (2013).
30. Lukacs, K. et al. The type 2 diabetes-associated variant in TCF7L2 is associated with latent autoimmune diabetes in adult Europeans and the gene effect is modified by obesity: a meta-analysis and an individual study. *Diabetologia* **55**, 689–693 (2012).

31. Itagaki, T. et al. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. *Gut* **54**, 1782–1789 (2005).

32. Cheng, X. et al. Effects of estradiol and progesterone on tumor necrosis factor alpha-induced apoptosis in human hepatoma HuH-7 cells. *Life Sci* **79**, 1988–1994 (2006).

33. Jelenik, T. & Roden, M. How estrogens prevent from lipid-induced insulin resistance. *Endocrinology* **154**, 989–992 (2013).

34. Piccinato, C. A., Rosa, G. J., N’Jai, A. U., Jefcoate, C. R. & Wilbank, M. C. Estradiol and progesterone exhibit similar patterns of hepatic gene expression regulation in the bovine model. *Plos One* **8**, e73552 (2013).

35. Jiao, P., Feng, B., Li, Y., He, Q. & Xu, H. Hepatic ERK activity plays a role in energy metabolism. *Mol Cell Endocrinol* **375**, 157–166 (2013).

36. Norton, L. et al. Chromatin occupancy of transcription factor 7-like 2 (TCF7L2) and its role in hepatic glucose metabolism. *Diabetologia* **54**, 3132–3142 (2011).

37. Norton, L. et al. The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells. *Nucleic Acids Res* **42**, 13646–13661 (2014).

38. Root-Bernstein, R., Podufaly, A. & Dillon, P. F. Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro. *Front Endocrinol (Lausanne)* **5**, 118 (2014).

39. Sharma, G. & Prossnitz, E. R. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. *Endocrinology* **152**, 3030–3039 (2011).

Acknowledgements
The authors thank EnPapers, Inc., for the English language editing service. This work was supported by the National Natural Science Foundation of China (81470892) and Zhejiang Provincial Natural Science Foundation (LY12H07005).

Author Contributions
F.D. analyzed data and wrote the manuscript. Q.L. conceived the study, designed and performed experiments. D.Y., Z.Z., J.S. and G.C. performed experiments. Y.F. and C.L. interpreted data. All authors finally approved this version to be published. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Dong, F. et al. TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis. *Sci. Rep.* **6**, 24859; doi: 10.1038/srep24859 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/